It is delightful that Her Majesty’s Government has arranged its communication of fiscal policy to serve also as a means of promoting the interests of the British theatre in its Christmas pantomime season manifestation. These are the kind of business friendly economic efficiencies we need! The manufacturing of theatrical reality is as much part of…
British Land shares at 818p after the interim results for the half year to 30th of September. The shares on the basis of the increase in the net asset value look as though they want to trade up again towards the top of this year’s trading range, where they would be selling at net asset…
The Next (NXT) 7,835p share price valuation seems to assume low earnings growth in comparison with the rates actually achieved over the last five years. It has also become a high dividend paying stock – at least for this year and next according to consensus forecasts. The company is still growing its store and directory…
Sainsbury at 253p after the interim results. The traditional quoted food retail sector is still undergoing a big change on an undetermined time scale. On that basis, Sainsbury shares may not look an obvious buy. However, I argue that the shares are attractive when the financial fundamentals are recognised. The shares, after the results of the first half of the current year, are…
Marks and Spencer at 507p, after the recent results for the six months to 26 September 2015. The encouraging features included better cash flow, further growth and progress in food, improving margins on general merchandising, and a telling 6.3% increase in the interim dividend. As a man who was previously unwilling to throw Marks and…
Rolls-Royce shares at 513p following the trading statement. The explanation of the latest downgrade (they come in threes like buses) is still a bit obscure and needs further explanation. However, I feel the shares are good value longer term and once the short term mists have lifted, will be an appropriate addition to a long…
For Standard Chartered bank at 600p (last seen) the Sands of time run out as Winter arrives. Are things as bad as they look or is this really the bottom? This has been the fortnight of Asian bank reporting. We have just had the third quarter results from HSBC (HSBA) which were well received by…
GlaxoSmithKline (GSK) has produced the following helpful, explanation of its pipeline of product development. Very simply, GSK has the potential to file up to 20 candidate medicines with regulators before 2020; seven of which are in advanced late-stage development, offering, if finally approved, potential market launches before 2020. That suggests potential for plenty of positive…
HSBC has done remarkably well for a bank that has most of its business in China and Asia. Moreover, it looks bombed out in valuation terms and appears, on the current share price, to have more upside than downside. I suspect, that even the near term share price is more likely to be up than…
It is bad news! The worst! Highly strung, highly paid investment banking economists are to be seen standing on the ledges of the top floors of investment banking skyscrapers, ready to hurl themselves off. Market and strategic analysts are reporting to suburban psychiatrists to get their neurosis levels topped up before committing frantic prose to…
